Form 4 for PHVS Pharvaris N.V.
Accepted 2026-07-01 19:02:33 ET · period of report 2026-06-29 · accession 0001193125-26-292956 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-01 19:02 | 2026-06-29+ | PHVS | Lesage Anne | Chief Early Development | M - OptEx | $6.85 | +38.5K | 86.6K | +80% | +$263.4K |
| DMT | 2026-07-01 19:02 | 2026-06-29+ | PHVS | Lesage Anne | Chief Early Development | S - Sale+OE | $35.37 | -38.5K | 58.8K | -40% | -$1.36M |
| DMTI | 2026-07-01 19:02 | 2026-06-29+ | PHVS | Lesage Anne | Chief Early Development | S - Sale+OE | $35.41 | -37.7K | 94.0K | -29% | -$1.33M |
| DMT | 2026-07-01 19:02 | 2026-06-29+ | PHVS | Lesage Anne | Chief Early Development | M - OptEx | $0.00 | -37.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | M | A | 1,400 | $2.59 | 57,850 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 2 | Common | Common Stock | 2026-06-29 | M | A | 900 | $8.05 | 58,750 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 3 | Common | Common Stock | 2026-06-29 | M | A | 4,100 | $2.59 | 56,450 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 4 | Common | Common Stock | 2026-06-29 | M | A | 4,200 | $8.05 | 67,050 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 5 | Common | Common Stock | 2026-06-29 | S | D | 2,300 | $35.12 | 56,450 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F2) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2026-06-29 | S | D | 8,300 | $35.05 | 58,750 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F3) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 7 | Common | Common Stock | 2026-06-30 | M | A | 2,972 | $2.59 | 61,722 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 8 | Common | Common Stock | 2026-06-30 | M | A | 24,900 | $8.05 | 86,622 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 9 | Common | Common Stock | 2026-06-30 | S | D | 27,872 | $35.48 | 58,750 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F4) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 10 | Common | Common Stock | 2026-06-29 | S | D | 6,997 | $35.05 | 124,672 | I By GrayMatters Consulting BVBA | — | — | (F5) This is a scheduled sale from 10b5-1 trading plan. (F6) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. (F7) GrayMatters Consulting B.V., an entity controlled by Dr. Lesage |
| 11 | Common | Common Stock | 2026-06-30 | S | D | 30,703 | $35.49 | 93,969 | I By GrayMatters Consulting BVBA | — | — | (F5) This is a scheduled sale from 10b5-1 trading plan. (F8) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. (F7) GrayMatters Consulting B.V., an entity controlled by Dr. Lesage |
| 12 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 4,200 | $0.00 | 69,900 | D | $8.05 · — to 2033-04-06 | 4,200 Common Stock | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F9) 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 13 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 24,900 | $0.00 | 45,000 | D | $8.05 · — to 2033-04-06 | 24,900 Common Stock | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F9) 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 14 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 1,400 | $0.00 | 7,072 | D | $2.59 · — to 2030-01-01 | 1,400 Common Stock | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F10) 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 15 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 4,100 | $0.00 | 2,972 | D | $2.59 · — to 2030-01-01 | 4,100 Common Stock | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F10) 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| 16 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 2,972 | $0.00 | 0 | D | $2.59 · — to 2030-01-01 | 2,972 Common Stock | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F10) 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. |